Your Cart Is Empty!
As expected, Sanofis incoming CEO will have a shiny new product franchise to launch when he takes the helm in April. The French company confirmed on Wednesday that Toujeo - a more potent version of its $7 billion-a-year Lantus franchise - has been approved by the FDA and will reach the US market in Q2.
Olivier Brandicourt and his team have some interesting decisions to make, however. Versus previous suggestions from Sanofi that Toujeo may be priced at a premium to Lantus, labelling approved by the FDA provides no mention of a nocturnal hypoglycaemic benefit for Toujeo.
Such a distinction, although not statistically significant, was demonstrated in Phase III head-to-head clinical studies and Sanofi may be able to leverage data published in medical journals to support its marketing effort, suggested analysts at JP Morgan. Furthermore, labelling for Toujeo reflects the "lack of significant weight" that the FDA places on nocturnal hypoglycaemia, they add, which could prevent Novo Nordisks Tresiba from gaining such a claim in the future.
This appears to be little consolation in the view of other analysts, however. Analysts at Bank of America Merrill Lynch described Toujeos label as "weak" but in line with their bearish expectations, while those at Bernstein suggested the label was less differentiated than most investors had expected.
Launch of Toujeo will be watched with great interest, given Sanofis recent need to cut prices to retain share for Lantus and the expected launch of Novo Nordisks Tresiba and Eli Lilly/Boehringer Ingelheims biosimilar Lantus over the next few years, which are expected to further increase the competitiveness of the market and could stoke a price war similar to that witnessed in hepatitis C.
Confirmation that Eli Lilly has postponed regulatory submissions for its branded basal insulin peglispro has also upped the ante, by potentially providing more rationale for biosimilar Lantus to be priced at a greater discount (ViewPoints: Delayed or departed? - the fate of Eli Lillys peglispro and implications for its biosimilar Lantus launch).
These factors will certainly shape the pricing strategy for Toujeo, with Sanofi now faced with the challenge (given its label) of convincing not only patients and physicians of its attributes, but also payers, warned Bernsteins Tim Anderson. While Sanofi will not disclose the price of Toujeo until launch, Anderson argues that a 15 percent discount versus Lantus will be necessary to gain traction with payers.
With Toujeo now approved, we are polling US-based endocrinologists to ascertain how they anticipate using the product and how they expect it to perform. Specifically we are asking them
Labelling for the newly approved basal insulin Toujeo (insulin glargine; see http://products.sanofi.us/Toujeo/Toujeo.pdf) provides no mention of a nocturnal hypoglycaemia benefit versus Lantus (it states "there were no clinically important differences in hypoglycaemia between Toujeo and Lantus in Type 1 diabetes patients"). This eliminates the primary point of differentiation for Toujeo versus Lantus.
- Completely disagree
- Somewhat disagree
- Neither agree or disagree
- Somewhat agree
- Completely agree
Toujeo requires one third of the injection volume to deliver the same number of insulin units as compared to Lantus and has effectively demonstrated non-inferiority in terms of efficacy. In your opinion, what level of advantage does Toujeo provide over Lantus?
- No advantage
- Slight advantage
- Moderate advantage
- Significant advantage
- Very significant advantage
What proportion of existing Lantus patients would you anticipate switching to treatment with Toujeo by the end of 2015 (assuming a Q2 launch for Toujeo)?
Based on its label, what are you expectations for uptake of Toujeo over the next few years?
- Very poor
Based on your assessment of Toujeo versus Lantus, what is your view on how Toujeo should be priced (in order to support moderate uptake)?
- Toujeo should be priced at a premium to Lantus - it is a superior product
- Toujeo should be priced at parity with Lantus
- 1-10 percent discount
- 11-20 percent discount
- 21-30 percent discount
- 31-40 percent discount
- 41-50 percent discount
- 50 percent-plus discount
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.